180 results on '"Tabayashi, Takayuki"'
Search Results
2. Secondary central nervous system involvement in patients with diffuse large B-cell lymphoma treated with rituximab combined CHOP therapy – a supplementary analysis of JCOG0601
3. Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effects
4. Lipidomic profiling of plasma from patients with multiple myeloma receiving bortezomib: an exploratory biomarker study of JCOG1105 (JCOG1105A1)
5. Successful Treatment of Disseminated Nocardiosis by Rapid Identification of the Organism via Genetic Analysis in a Leukemia Patient Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
6. HL-252 MCVAC Conditioning Regimen Followed by Autologous Hematopoietic Stem Cell Transplantation in Patients With Relapsed and Refractory Hodgkin Lymphoma: A Single-Institution Retrospective Study
7. POSTER: HL-252 MCVAC Conditioning Regimen Followed by Autologous Hematopoietic Stem Cell Transplantation in Patients With Relapsed and Refractory Hodgkin Lymphoma: A Single-Institution Retrospective Study
8. Successful early romiplostim use in a case of severe immune thrombocytopenia with critical carotid arterial injury
9. Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant‐ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105
10. Interim PET-Guided ABVD or ABVD/Escalated BEACOPP for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma (JCOG1305, INNOVATE-HL study)
11. Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3
12. P1-261 - Up-front high-dose chemotherapy followed by autologous stem cell transplantation for high-risk aggressive lymphoma
13. Rapid deterioration of intravascular large B-cell lymphoma with mass formation in the trigeminal nerve and multiple organ infiltration: An autopsy case report
14. TM-233, a novel analog of 1′-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities
15. P-126: The prognostic impact of the UK Myeloma Research Alliance Risk Profile in untreated patients with multiple myeloma who received melphalan, prednisolone, and bortezomib: an ad hoc analysis of JCOG1105
16. The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis
17. Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation
18. P1-2-61 - Therapeutic approach for primary plasma cell leukemia: case reports and a review of the literature
19. Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients
20. Rapid Improvement of Disseminated Intravascular Coagulation by Donor Leukocyte Infusions in a Patient with Promyelocytic Crisis of Chronic Myelogenous Leukemia after Reduced-Intensity Stem Cell Transplantation from an HLA 2-Antigen—Mismatched Mother
21. SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F
22. Characterization of the short isoform of Helios overexpressed in patients with T-cell malignancies
23. Elevation of serum hepatocyte growth factor during granulocyte colony-stimulating factor-induced peripheral blood stem cell mobilization
24. Successful Eradication of Residual bcr-abl-Positive Clones by Donor Leukocyte Transfusion in a Patient With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia After Peripheral Blood Stem Cell Transplantation
25. The type 1 CD10/neutral endopeptidase 24.11 promoter: functional characterization of the 5′-untranslated region
26. Over-expression of the dominant-negative isoform of Ikaros confers resistance to dexamethasone-induced and anti-IgM-induced apoptosis
27. Over-expression of short isoforms of Helios in patients with adult T-cell leukaemia/lymphoma
28. Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center‐derived B‐cell lymphomas
29. The clinical impact of absolute lymphocyte count in peripheral blood among patients with methotrexate - associated lymphoproliferative disorders
30. Overexpression of novel short isoforms of Helios in a patient with T-cell acute lymphoblastic leukemia
31. Dual Targeting of Cell-Cycle Checkpoint Kinase and Unfolded Protein Response As a Novel Therapeutic Approach for High-Risk Multiple Myeloma with TP53 Deletion or Mutations
32. Advances in therapeutic approaches for multiple myeloma
33. Abstract 1884: Dual targeting of cell cycle checkpoint and histone deacetylase overcomes bortezomib resistance in multiple myeloma
34. The Absolute Count of Lymphocytes Is a Strong Predictive Factor for Relapse/Regrowth Events and Outcomes in Patients with Regressive Methotrexate-Associated Lymphoproliferative Disorders
35. Up-front high-dose chemotherapy followed by autologous stem cell transplantation for high-risk aggressive lymphoma
36. The aggressive clinical courses of Hodgkin lymphoma primarily diagnosed as methotrexate-induced non-specific lymphoproliferative disorder in patients with rheumatoid arthritis
37. Inhibition of WEE1 Induces Cell Death of Both Bortezomib- and Lenalidomide-Resistant Multiple Myeloma Cells: A Novel Therapeutic Approach Targeting Cell-Cycle Checkpoint Kinase
38. CD14-CD15+, Possible Cells Are Potent Myeloid-Derived Suppressor Cells, Which Affect the Pathogenesis of Induction and Regression in Methotrexate-Mediated Lymphoproliferative Disorders
39. Successful early romiplostim use in a case of severe immune thrombocytopenia with critical carotid arterial injury
40. SY15-2 - Advances in therapeutic approaches for multiple myeloma
41. The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches
42. Novel Therapeutic Approach to Overcome Both Bortezomib- and Lenalidomide-Resistant Multiple Myeloma By Targeting TOPK/PBK
43. Therapeutic approach for primary plasma cell leukemia: case reports and a review of the literature
44. TM ‐233, a novel analog of 1′‐acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK / STAT and proteasome activities
45. Successful Management of Transplant-Ineligible Patients with Refractory/Relapsed Multiple Myeloma By Using a Biweekly or Longer Modified Bortezomib Schedule As Interval Maintenance therapy
46. Targeting the Wnt/β-Catenin Signaling Pathway in Multiple Myeloma: A Possible New Therapeutic Approach to Overcome Bortezomib-Resistance
47. Efficacy of Low-Dose Cytarabine-Based Regimen(Cag)Followed by Azacitidine for Elderly Patients with Mds/Aml
48. Docetaxel for non small cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation
49. Therapy-Related Myeloid Neoplasm in Methotrexate-Associated Lymphoproliferative Disease in a Rheumatoid Arthritis Patient
50. TM-233 Exerts Anti-Myeloma Activity and Overcomes Bortezomib-Resistance In Human Multiple Myeloma Cells By Targeting NF-κB and JAK/STAT Dual-Signaling Pathways
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.